These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25356732)

  • 1. Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
    Ellenbroek BA; Prinssen EP
    Behav Pharmacol; 2015 Feb; 26(1-2):33-44. PubMed ID: 25356732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct activation by dopamine of recombinant human 5-HT1A receptors: comparison with human 5-HT2C and 5-HT3 receptors.
    Oz M; Zhang L; Rotondo A; Sun H; Morales M
    Synapse; 2003 Dec; 50(4):303-13. PubMed ID: 14556235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise-induced hippocampal neurogenesis: 5-HT
    Kim DD; Barr AM; Honer WG; Procyshyn RM
    Mol Psychiatry; 2018 Dec; 23(12):2252-2253. PubMed ID: 29422519
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.
    du Jardin KG; Jensen JB; Sanchez C; Pehrson AL
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):160-71. PubMed ID: 23916504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia.
    Schuhmacher A; Mössner R; Quednow BB; Kühn KU; Wagner M; Cvetanovska G; Rujescu D; Zill P; Möller HJ; Rietschel M; Franke P; Wölwer W; Gaebel W; Maier W
    Pharmacogenet Genomics; 2009 Nov; 19(11):843-51. PubMed ID: 19794330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsteroidal anti-inflammatory drugs and 5-HT₃ serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia.
    Andrade C
    J Clin Psychiatry; 2014 Jul; 75(7):e707-9. PubMed ID: 25093487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
    Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
    Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of serotonin in the action of atypical antipsychotic drugs.
    Meltzer HY
    Clin Neurosci; 1995; 3(2):64-75. PubMed ID: 7583621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT(3) receptors: role in disease and target of drugs.
    Walstab J; Rappold G; Niesler B
    Pharmacol Ther; 2010 Oct; 128(1):146-69. PubMed ID: 20621123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of serotonin in antipsychotic drug action.
    Meltzer HY
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):106S-115S. PubMed ID: 10432496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC; Seamans JK
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
    Rojas C; Raje M; Tsukamoto T; Slusher BS
    Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin-dopamine interaction and its relevance to schizophrenia.
    Kapur S; Remington G
    Am J Psychiatry; 1996 Apr; 153(4):466-76. PubMed ID: 8599393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential serotonergic agents for the treatment of schizophrenia.
    Garay RP; Bourin M; de Paillette E; Samalin L; Hameg A; Llorca PM
    Expert Opin Investig Drugs; 2016; 25(2):159-70. PubMed ID: 26576669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.